CTLA4 and neoplasm: Additionally, the ONC-392 trial (NCT04140526) explores an anti-CTLA-4 antibody alone or combined with pembrolizumab in patients with advanced solid tumors, including OSCC, aiming to enhance anti-tumor immunity with reduced toxicity.